NYSE: JNJ
Johnson & Johnson Earnings & Revenue

JNJ past earnings growth

How has JNJ's earnings growth performed historically?
Company
21.43%
Industry
10.68%
Market
82.89%
JNJ's earnings have grown slower (4.04% per year) than the US Drug Manufacturers - General industry average (8.89%)
Performance
JNJ's earnings have grown slower (4.04% per year) than the US market average (77.34%)
Performance
JNJ's earnings growth is accelerating - its growth over the last year (21.43%) is above its 5-year compound annual rate (4.04%)
Performance

JNJ past revenue growth

How has JNJ's revenue growth performed historically?
Company
-1.04%
Industry
6.62%
Market
16.55%
JNJ's revenue has grown slower (2.77% per year) than the US Drug Manufacturers - General industry average (4.07%)
Performance
JNJ's revenue has grown slower (2.77% per year) than the US market average (15.67%)
Performance
JNJ's revenue growth is slowing down - its growth over the last year (-1.04%) is below its 5-year compound annual rate (2.77%)
Performance

JNJ earnings and revenue history

Current Revenue
$80.9B
Current Earnings
$17.0B
Current Profit Margin
21%
JNJ's has not demonstrated consistent long-term earnings growth over the past 10 years (30.77%)
Performance

JNJ Return on equity

Current Company
27.4%
Current Industry
35.2%
Current Market
13.3%
JNJ's Return on Equity (27.4%) shows a company that is highly efficient at transforming shareholder equity into returns
Performance

JNJ Return on assets

Current Company
10.6%
Current Industry
9.7%
Current Market
7.1%
JNJ is generating higher Return on Assets (10.6%) than the US Drug Manufacturers - General industry average (8.27%)
Performance

JNJ Return on capital employed

Current Company
14.61%
Current Industry
15.1%
JNJ's ability to generate Return on Capital (14.61%) has decreased compared to 3 years ago (16.38%)
Performance

Johnson & Johnson Earnings & Revenue FAQ

On Apr 14, 2020, Johnson & Johnson (NYSE: JNJ) reported Q1 2020 earnings per share (EPS) of $2.20, up 56.03% year over year. Total Johnson & Johnson earnings for the quarter were $5.80 billion. In the same quarter last year, Johnson & Johnson's earnings per share (EPS) was $1.41.
On Apr 14, 2020, Johnson & Johnson (NYSE: JNJ) reported Q1 2020 revenue of $20.69 billion up 3.35% year over year. In the same quarter last year, Johnson & Johnson's revenue was $20.02 billion.
As of Q4 2020, Johnson & Johnson's earnings has grown 21.43% year over year. This is 10.75 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of 10.68%. Johnson & Johnson's earnings in the past year totalled $16.99 billion.
As of Q4 2020, Johnson & Johnson's revenue has grown -1.04% year over year. This is 7.66 percentage points lower than the US Drug Manufacturers - General industry revenue growth rate of 6.62%. Johnson & Johnson's revenue in the past year totalled $80.86 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics